The recently approved glucagon-like peptide-1 receptor agonists (GLP1RA) have been groundbreaking in their ability to treat diabetes and obesity with a comparatively benign side effect profile. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.